Elthera develops an antibody drug conjugate ELT048 against a novel target L1CAM whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various cancer types like ovarian, pancreatic, lung, colorectal cancer and melanoma.

Products, services, technology

The clinical candidate ELT048, an anti-L1CAM ADC has demonstrated excellent efficacy in several solid tumor in vivo models and safety in non-human primates.

Cooperation possibilities

We are looking for investors and / or strategic pharma partners for the preclinical and clinical development of our ELT048.

Location

Brandstrasse 24, 8952 Schlieren, Schweiz

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2016
  • Number of employees in Switzerland
    1-9
Key business